Scancell: Poised for several pivotal clinical events in 2025
Scancell achieved more in 2024 than in any previous year, but it is the important clinical catalysts for its lead cancer vaccines due this year that are the main focus. The key readouts include further Phase II data for SCIB1 with a doublet checkpoint (CPI) in advanced skin cancer, first clinical data in the same setting with the second-generation iSCIB1+, and key CPI combination data for Modi-1 in multiple solid tumours. In addition, the GlyMab and AvidiMab platforms provide attractive out-licensing opportunities. The December 2024 fundraise, coupled with Genmab milestone income, extends the cash runway into H226, beyond key clinical catalysts, and provides the flexibility to explore partnering or out-licensing activities of key assets. Data and business development will help to define the commercial prospects for the pipeline. Our updated Scancell rNPV valuation is £330m, or 32p per share.Scancell Holdings is engaged in the discovery and development of novel vaccines for the treatment of cancer based on its proprietary immuno-oncology platforms, ImmunoBody®, and Moditope®. Co.'s ImmunoBody® consist of SCIB1 melanoma vaccine, and SCIB2 lung cancer vaccine. Co. has a collaboration partnership to evaluate the use of its SCIB2 to treat non-small cell lung cancer. Co.'s Moditope® technology is a vaccine platform that targets neo-epitopes to overcome immune suppression induced by tumour cells. Co.'s Moditope® product, Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide for the treatment of breast cancer, ovarian cancer and sarcoma.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.